Tessera Defense and Homeland Security Inc
biomx.comWhat Do They Do?
Develops phage-based treatment candidates for people with chronic diseases linked to harmful bacteria, including diabetic foot infections and bone infections.
10-K for FY2025, filed Feb 19, 2026We are a clinical stage product discovery company developing products using both natural and engineered phage technologies designed to…View ↗
BX011 is a fixed multi-phage cocktail, for the treatment of DFI associated with Staphylococcus aureus, or S. aureus, a key bacterium…View ↗
BX211 is a phage therapy for the treatment of DFO associated with S. aureus. The personalized phage treatment tailors a specific phage…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Feb 19, 2026
How Are They Changing?
-
Aug 11, 2026
Agreed to buy a minority stake in an electric-motor testing business
The purchase depends on exchange approval and a worldwide license to the company’s technology and know-how.
Sources
8-K, filed Aug 11, 2026
On August 5, 2026, BiomX Inc., a Delaware corporation (“BiomX” or the “Company”) entered into a Share Purchase and Option Agreement (the…View ↗
-
Jul 2, 2026
Changed its independent auditor
Barzily & Co. replaced Kesselman & Kesselman effective July 1, 2026.
Sources
8-K, filed Jul 2, 2026
On July 1, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of BiomX Inc. (the “Company”)…View ↗
Program focus
Earlier product-program descriptions centered on cystic fibrosis and atopic dermatitis; the latest lists diabetic foot infections and diabetic foot osteomyelitis as ongoing programs, and describes the cystic fibrosis candidate as discontinued.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Feb 19, 2026BX011 - Treatment of Diabetic Foot Infections, or DFIView ↗
BX211 – Treatment of Diabetic Foot Osteomyelitis (DFO)View ↗
BX004 – Treatment of Cystic FibrosisView ↗
In light of the foregoing, and as detailed above, in December, 2025, we discontinued the development of BX004, following internal analysis…View ↗
Who Do They Compete With?
Competes with Locus Biosciences, Armata Pharmaceuticals, SNIPR Biome, Technophage, and Phaxiam
10-K for FY2025, filed Feb 19, 2026We are aware of a number of biotechnology companies developing bacteriophage products to treat diseases. To our knowledge, several…View ↗
Loading...
